title: Objective response of multiple myeloma to cyclosporin A.
abstract: Two patients with advanced multiple myeloma were treated with oral low-dose cyclosporin A. one without other therapy and one in conjunction with chemotherapy to which the patient had been previously unresponsive. Both patients had objective laboratory and clinical responses. In the patient treated with cyclosporin A alone, decreasing serum IL-6 and beta-2-microglobulin levels fell as the clinical response evolved. Cyclosporin A deserves further evaluation in the therapy of multiple myeloma.
authors.affiliation: Department of Oncology and Medicine, Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, New York.
authors.forename: P H
authors.initials: PH
authors.lastname: Wiernik
authors.forename: J P
authors.initials: JP
authors.lastname: Dutcher
authors.forename: A N
authors.initials: AN
authors.lastname: Leaf
authors.forename: Z
authors.initials: Z
authors.lastname: Liao
authors.forename: E
authors.initials: E
authors.lastname: Paietta
authors.forename: D L
authors.initials: DL
authors.lastname: Rosenstreich
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016572:Cyclosporine / Q000008:administration & dosage / Q000627:therapeutic use*; D003907:Dexamethasone; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D016572:Cyclosporine